+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Endometriosis in Italy: from cost estimates to new medical treatment



Endometriosis in Italy: from cost estimates to new medical treatment



Gynecological Endocrinology 25(11): 734-740



Endometriosis is defined as the presence of endometrial-like tissue outside the uterus, which induced a chronic inflammatory reaction. The data collected from Italy showed that around 3 million women are affected by endoemtriosis and the condition was predominantly found in women of reproductive age (50% of women were in the 29-39 age range), only 25% of women were asymptomatic. The associated symptoms can create an impact in general physical, mental, and social well-being. Endometriosis is associated with severe dysmenorrhea, deep dyspareunia, chronic pelvic pain, ovulation pain, cyclical, or perimenstrual symptoms, with or without abnormal bleeding, infertility, and chronic fatigue. The annual cost for hospital admission can be estimated to be in a total around 54 million euros. The average time for right diagnosis is around 9 years still today and it follows a long and expensive diagnostic search. Therapies can be useful to relieve and sometimes solve the symptoms, encourage fertility, eliminate endometrial lesions, and restore the anatomy of the pelvis. For medical therapy, several different preparations (oral contraceptives, progestogenics, gestrinone, danazol, and GnRHa) and new options (GnRH antagonists, aromatase inhibitors, estrogen receptor beta agoinist, progesterone receptor modulators, angiogenesis inhibitors, and COX-2 selective inhibitors) are available.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052963099

Download citation: RISBibTeXText

PMID: 19908951

DOI: 10.3109/09513590903159664


Related references

Cost-Effectiveness of Recommended Medical Intervention for Treatment of Dysmenorrhea and Endometriosis in Japan Setting. Value in Health 18(7): A736-A737, 2015

Endometriosis: cost estimates and methodological perspective. Human Reproduction Update 13(4): 395-404, 2007

Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. American Journal of Managed Care 11(4 Suppl): S130-S139, 2005

Surgical procedures and their cost estimates among women with newly diagnosed endometriosis: a US database study. Journal of Medical Economics 14(1): 115-123, 2011

Impact of medical and surgical treatment of endometriosis on the cure of endometriosis and pain. Biomed Research International 2014: 264653-264653, 2015

Thresholds for the use of recombinant human colony-stimulating factors based on revised cost estimates incorporating indirect medical, nonmedical and intangible cost considerations. Blood 88(10 SUPPL 1 PART 1-2): 346A, 1996

Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 45(2): 171-178, 2004

Colloquium on endometriosis. VI. Medical treatment of endometriosis. Cirugia Y Cirujanos 36(2): 145-150, 1968

The medical treatment of endometriosis and the significance of endometriosis. Surgery, Gynecology & Obstetrics 89(3): 317-321, 1949

Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK. Applied Health Economics and Health Policy 4(1): 23-35, 2005

The cost of inpatient endometriosis treatment: an analysis based on the Healthcare Cost and Utilization Project Nationwide Inpatient Sample. American Journal of Managed Care 4(8): 1127-1134, 1998

Is subtotal thyroidectomy a cost-effective treatment for Graves disease? A cost-effectiveness analysis of the medical and surgical treatment options. Surgery 152(2): 164-172, 2012

Patient-Level Estimates of Diabetic Complications on Direct Medical Cost. Value in Health 17(7): A340-A340, 2014

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy. Clinicoeconomics and Outcomes Research 4(): 237-243, 2012

Preliminary investigation of genetic services in texas usa needs assessment and medical cost estimates. American Journal of Human Genetics 45(4 SUPPL): A279, 1989